Dental Sleep Medicine: Oral Appliances for Obstructive Sleep Apnea

Dental sleep medicine represents one of the most significant expansions of the dentist's scope of practice in the twenty-first century. Obstructive sleep apnea (OSA)—characterized by recurrent episodes of partial (hypopnea) or complete (apnea) upper airway collapse during sleep, resulting in oxygen desaturation and arousal from sleep—affects approximately 25% of adult men and 10% of adult women in the United States, with prevalence rising in parallel with the obesity epidemic. The consequences of untreated moderate to severe OSA (apnea-hypopnea index, AHI, of 15 or greater) include a two- to threefold increased risk of cardiovascular disease (hypertension, myocardial infarction, stroke, atrial fibrillation), metabolic syndrome and type 2 diabetes, neurocognitive impairment (excessive daytime sleepiness, impaired concentration, increased motor vehicle accident risk), and increased all-cause mortality. The dentist's role in managing OSA through oral appliance therapy (OAT) has been formally recognized by the American Academy of Dental Sleep Medicine (AADSM) and the American Academy of Sleep Medicine (AASM), which recommends OAT as a first-line treatment for mild to moderate OSA and as a second-line treatment for severe OSA in patients who are intolerant of or non-adherent to continuous positive airway pressure (CPAP) therapy.

Pathophysiology of Obstructive Sleep Apnea

OSA results from the interplay of anatomical and physiological factors that predispose to pharyngeal collapse during sleep. The pharyngeal airway lacks rigid cartilaginous or bony support; its patency depends on the balance between the negative intraluminal pressure generated by diaphragmatic contraction during inspiration and the dilating forces exerted by the pharyngeal dilator muscles (primarily the genioglossus, which protrudes the tongue). During sleep, the loss of wakefulness drive reduces genioglossus tone, narrowing the pharyngeal lumen. In individuals with a structurally narrow pharyngeal airway—due to obesity (parapharyngeal fat deposition), craniofacial morphology (mandibular retrognathia, maxillary constriction, inferiorly positioned hyoid bone), or soft tissue enlargement (macroglossia, elongated soft palate, hypertrophic tonsils)—the reduction in pharyngeal dilator tone is sufficient to permit collapse, particularly during REM sleep when muscle atonia is maximal.

Two additional physiological mechanisms compound the anatomical vulnerability: (1) loop gain, the sensitivity of the ventilatory control system, where exaggerated swings in ventilatory drive in response to apnea produce hypocapnia that further suppresses respiratory drive, perpetuating the cyclical pattern of apnea and hyperventilation, and (2) the arousal threshold, where the degree of respiratory effort required to trigger a cortical arousal determines how long an apnea persists—a low arousal threshold fragments sleep but limits desaturation, while a high arousal threshold results in prolonged apneas with more severe desaturation.

Diagnosis and Indications for Oral Appliance Therapy

Polysomnography and Home Sleep Testing

The gold standard for OSA diagnosis is in-laboratory attended polysomnography (PSG), which records electroencephalography (sleep staging and arousals), electrooculography (eye movements), electromyography (chin and leg muscle tone), electrocardiography, airflow (nasal pressure transducer and oronasal thermistor), respiratory effort (thoracic and abdominal inductance plethysmography belts), oxygen saturation (pulse oximetry), body position, and snoring (microphone). The AHI—the average number of apneas and hypopneas per hour of sleep—is calculated from these data. Home sleep apnea testing (HSAT) using portable monitoring devices that record a subset of PSG channels (typically airflow, respiratory effort, oxygen saturation, and heart rate) is a validated alternative for patients with high pretest probability of moderate to severe OSA and without significant comorbidities (severe cardiopulmonary disease, neuromuscular disorders, or suspected other sleep disorders such as narcolepsy or parasomnia).

Severity Classification and Treatment Indications

OAT is also indicated for primary snoring (simple snoring without apnea or hypopnea) when the patient seeks treatment for social reasons (bed partner disturbance) and conservative measures (weight loss, positional therapy, avoidance of alcohol and sedatives before sleep) have been unsuccessful.

Oral Appliance Types and Mechanisms of Action

Mandibular Advancement Devices (MADs)

Mandibular advancement devices are the most extensively studied and clinically used oral appliances for OSA and snoring. The MAD is a two-piece appliance that fits over the maxillary and mandibular dental arches, connected by a mechanism that holds the mandible in a protruded position relative to the maxilla. The therapeutic mechanism is mechanical: mandibular protrusion pulls the tongue base and attached soft tissues (genioglossus, geniohyoid, anterior belly of digastric) anteriorly, increasing the cross-sectional area of the velopharyngeal and oropharyngeal airway by 10-30% as measured by lateral cephalometry or dynamic MRI. This increases the critical closing pressure (Pcrit) required for airway collapse, reducing the frequency and severity of obstructive events.

MAD design features:

• Custom-fabricated vs. prefabricated (boil-and-bite): Custom-fabricated appliances, manufactured from dental impressions by a dental laboratory, provide superior retention, comfort, and efficacy compared to prefabricated devices. The AASM recommends custom-fabricated appliances. Prefabricated devices have lower cost but are associated with lower adherence, more side effects, and less predictable outcomes.
• Titratable vs. non-titratable: Titratable appliances allow the clinician (or patient, following instruction) to progressively increase mandibular protrusion by turning a screw or exchanging connector arms—typically in 0.5-1.0 mm increments—to identify the minimum effective protrusion. Non-titratable (monobloc) appliances are fixed at a single protrusion and do not permit adjustment; they are largely obsolete in contemporary practice due to lower efficacy and higher side effect rates.
• Material: Hard acrylic appliances with ball clasps (Adams clasps) or acrylic coverage provide superior retention. Softer, flexible materials (thermoplastic elastomers) are more comfortable but less retentive and may not maintain the prescribed protrusion during sleep bruxism.
• Vertical opening: Most MADs produce some degree of vertical opening, which can rotate the mandible clockwise and potentially narrow the oropharyngeal airway in the anteroposterior dimension. For this reason, appliances that minimize vertical opening (2-5 mm interincisal clearance) are preferred in patients with a high mandibular plane angle, as they reduce the risk of counteracting the therapeutic effect of protrusion.

Tongue-Retaining Devices (TRDs)

Tongue-retaining devices hold the tongue in an anterior position by suction, without mandibular protrusion. The TRD is indicated for edentulous patients (who lack the dental anchorage for a MAD), patients with severe periodontitis or insufficient teeth for MAD retention, and patients with temporomandibular joint (TMJ) disorders that preclude mandibular protrusion. The TRD's suction bulb is placed at the anterior aspect of the tongue; the negative pressure and surface friction maintain the tongue in the protruded position during sleep. TRDs are less comfortable and less well-tolerated than MADs in dentate patients, and the evidence base for their efficacy is more limited, consisting primarily of small case series rather than randomized controlled trials.

Clinical Workflow for Oral Appliance Therapy

1. Pretreatment evaluation: Review the diagnostic sleep study and the referring sleep physician's report confirming the diagnosis and OAT candidacy. Perform a comprehensive dental examination: dental charting, periodontal evaluation (periodontal probing depths, gingival recession, mobility, furcation involvement), TMJ evaluation (range of motion, joint sounds, palpation for myofascial pain), intraoral soft tissue examination, and occlusal analysis. Adequate periodontal health (no active periodontitis) and a minimum number of healthy teeth per arch (typically 8-10 teeth per arch for adequate appliance retention) are required. Inform the patient of expected benefits, potential side effects, and the shared-care model with the sleep physician.
2. Impressions and bite registration: Take maxillary and mandibular alginate or PVS impressions. Record the protrusive bite registration at approximately 60-70% of the patient's maximum mandibular protrusion, measured with a millimeter ruler or a George Gauge. This is the starting protrusion; the titration mechanism will allow progressive advancement from this baseline.
3. Appliance delivery: Insert the appliance, verify fit and retention, and confirm the protrusion setting matches the laboratory prescription. Instruct the patient on insertion and removal, cleaning protocol (soft toothbrush with mild soap or denture cleaner; avoid hot water which can warp acrylic), and storage (dry container when not in use).
4. Titration: The patient begins wearing the appliance at night. If tolerated, the protrusion is advanced by 0.5-1.0 mm every 3-7 days, guided by the patient's subjective report of snoring reduction (bed partner report) and daytime symptom improvement (Epworth Sleepiness Scale). The titration endpoint is either resolution of symptoms (bed partner reports no snoring, patient reports normal daytime alertness) or the maximum comfortable protrusion, whichever occurs first. Most patients achieve their therapeutic endpoint at 60-75% of maximum protrusion.
5. Therapeutic efficacy verification: After 2-3 months of OAT use (sufficient time to complete titration), a follow-up sleep study—either HSAT or in-laboratory PSG—with the appliance in place is required to objectively verify therapeutic efficacy. The definition of treatment success varies by study but generally includes one of the following: reduction of AHI by 50% or more from baseline, AHI less than 10 events/hour with the appliance, or AHI less than 5 events/hour (full resolution). Approximately 65-75% of patients with mild to moderate OSA achieve a 50% or greater reduction in AHI with optimally titrated custom MAD therapy. For non-responders, the dentist must collaborate with the sleep physician to explore alternative or combination therapies.
6. Long-term follow-up: Annual follow-up visits assess OAT adherence (reported hours per night, nights per week), ongoing efficacy (symptom recurrence, weight changes that can worsen OSA severity), occlusal changes, and appliance integrity. The appliance should be inspected for wear, cracks, and loss of retention. Replacement is typically required every 3-5 years due to material fatigue, though grossly obese patients who exert high occlusal forces during sleep bruxism may require replacement more frequently.

Side Effects and Management

Combination Therapy and Special Considerations

For patients who are partial responders to OAT (AHI reduced but not to the target threshold), combination therapy with OAT plus positional therapy (for supine-predominant residual OSA) or OAT plus CPAP (at a lower, more tolerable pressure made possible by the protrusion-induced airway enlargement) can be considered. The OAT-CPAP combination, while requiring the patient to use two devices, leverages the airway-stabilizing effect of mandibular protrusion to reduce the CPAP pressure requirement, improving adherence in patients who would otherwise abandon therapy entirely.

Special populations requiring modified approaches include: edentulous patients (impression copings placed in existing dentures, or fabrication of a MAD or TRD integrated with the dentures); patients with extensive fixed prostheses or implants (adequate retention is typically maintained, but the appliance design must avoid impingement on implant-supported restorations and implant soft tissue interfaces); and pediatric patients with OSA due to craniofacial anomalies (rapid maxillary expansion, rather than MAD therapy, is the dental treatment of choice for pediatric OSA with maxillary constriction, as it addresses the skeletal etiology).

Conclusion

Oral appliance therapy has earned its place as a validated, first-line treatment for mild to moderate OSA and a critical alternative for CPAP-intolerant severe OSA. The dentist practicing dental sleep medicine occupies a unique position at the interface of dentistry and sleep medicine, requiring proficiency in both the mechanical aspects of appliance therapy—impression-taking, bite registration, appliance delivery and titration—and the medical aspects of OSA—diagnostic criteria, sleep study interpretation, treatment efficacy evaluation, and the systemic health consequences of the disease. The collaborative care model with the sleep physician is non-negotiable: the dentist manages the appliance, but the physician manages the disease. When this collaboration functions optimally, the patient with OSA gains a treatment that is effective, well-tolerated, and—in the case of the custom-titratable MAD—capable of delivering a meaningful improvement in sleep quality, daytime function, and long-term cardiovascular health.